Want to see CYPH full AI Analyst Report?
Top Page
Cypherpunk Technologies
(NASDAQ:CYPH)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.71
Action:Reiterated
Date:06/23/26
The score is primarily constrained by very weak financial performance—minimal revenue, large ongoing losses, and substantial cash burn—despite low debt. Technical indicators also lean bearish with price below key moving averages and negative MACD. Corporate governance support is a minor positive, while valuation metrics are limited by the negative P/E and lack of dividend yield data.
Positive Factors
Low leverage
The company’s extremely low reported debt provides durable financial flexibility: it reduces interest and covenant risk, preserves borrowing capacity, and gives management optionality for future capital raises or strategic investments without immediate balance-sheet strain. This matters over months as a buffer against cash burn and for executing long-term plans.
Negative Factors
Severe cash burn
Persistent, large negative operating and free cash flow is a structural weakness: the business is not self‑funding and will likely need repeated external financing. Over months this raises dilution risk, constrains R&D or go‑to‑market spending, and limits the company’s ability to pursue strategic initiatives without securing new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
The company’s extremely low reported debt provides durable financial flexibility: it reduces interest and covenant risk, preserves borrowing capacity, and gives management optionality for future capital raises or strategic investments without immediate balance-sheet strain. This matters over months as a buffer against cash burn and for executing long-term plans.
Read all positive factors
Cypherpunk Technologies (CYPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$74.83M
Dividend YieldN/A
Average Volume (3M)5.50M
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue GrowthN/A
EPS Growth99.27%
CountryUS
Employees6
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding106,464,485
10 Day Avg. Volume1,809,373
30 Day Avg. Volume5,500,944
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.75
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Cypherpunk Technologies Business Overview & Revenue Model
Company Description
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-re...
How the Company Makes Money
null...
Cypherpunk Technologies Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
55
Neutral
Cash Flow
8
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.50M |
| Gross Profit | 0.00 | 0.00 | 0.00 | -427.00K | 0.00 | 1.50M |
| EBITDA | -56.75M | -36.54M | -70.05M | -80.99M | -54.38M | -40.54M |
| Net Income | -56.91M | 4.82M | -67.56M | -81.41M | -54.60M | -40.59M |
Balance Sheet | ||||||
| Total Assets | 87.38M | 163.18M | 49.12M | 72.83M | 58.09M | 117.91M |
| Cash, Cash Equivalents and Short-Term Investments | 6.69M | 14.04M | 47.25M | 70.64M | 43.76M | 114.92M |
| Total Debt | 38.00K | 38.00K | 266.00K | 262.00K | 524.00K | 469.00K |
| Total Liabilities | 3.00M | 9.68M | 14.08M | 12.68M | 3.45M | 10.02M |
| Stockholders Equity | 84.38M | 153.51M | 35.05M | 60.14M | 54.64M | 107.89M |
Cash Flow | ||||||
| Free Cash Flow | -42.82M | -43.90M | -60.30M | -43.75M | -49.04M | -35.16M |
| Operating Cash Flow | -40.83M | -43.90M | -60.30M | -43.75M | -49.04M | -35.16M |
| Investing Cash Flow | -92.01M | -97.00M | 0.00 | 48.97M | 0.00 | 0.00 |
| Financing Cash Flow | 113.12M | 107.65M | 37.18M | -30.00K | -210.00K | 98.03M |
Cypherpunk Technologies Technical Analysis
―
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYPH, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for CYPH.
Cypherpunk Technologies Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
* Financial Sector Average
Performance Comparison
Cypherpunk Technologies Corporate Events
Executive/Board ChangesShareholder Meetings
Cypherpunk Shareholders Back Board, Pay and Auditor Choices
Positive
Jun 22, 2026
At its 2026 Annual Meeting of Stockholders held on June 18, 2026, Cypherpunk Technologies Inc. shareholders elected Will McEvoy and Nissim Mashiach as Class III directors to serve until the 2029 annual meeting, reaffirming the company’s exis...
Executive/Board Changes
Cypherpunk Technologies Announces Planned Board Leadership Transitions
Neutral
Apr 10, 2026
On April 7, 2026, Cypherpunk Technologies said Class III directors Dr. Christopher Mirabelli and Dr. Joseph Loscalzo notified the company of their plans to retire from the Board and not stand for re‑election at the 2026 Annual Meeting, submi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.